TEVA
Teva Pharmaceutical Industries LimitedNYSEHealthcare$30.08-0.56%ClosedMarket Cap: $35.03B
As of 2026-04-06
Valuation
P/E (TTM)
24.86
PEG
0.13
P/B
4.33
P/S
2.00
EV/EBITDA
15.67
DCF Value
$25.37
FCF Yield
4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.8%
Operating Margin
18.2%
Net Margin
8.2%
ROE
20.1%
ROA
3.5%
ROIC
10.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $4.71B | 56.4% | $300.0M | $480.0M | $0.41 | — |
| FY 2025 | $17.26B | 51.8% | $2.16B | $1.41B | $1.20 | — |
| Q3 2025 | $4.48B | 51.4% | $882.0M | $433.0M | $0.37 | — |
| Q2 2025 | $4.18B | 50.3% | $455.0M | $282.0M | $0.24 | — |
| Q1 2025 | $3.89B | 48.2% | $519.0M | $214.0M | $0.18 | — |
| Q4 2024 | $4.23B | 50.1% | $-29.0M | $-217.0M | $-0.19 | — |
| FY 2024 | $16.54B | 48.7% | $-303.0M | $-1.64B | $-1.45 | — |
| Q3 2024 | $4.33B | 49.6% | $-51.0M | $-437.0M | $-0.39 | — |
| Q2 2024 | $4.16B | 48.6% | $-5.0M | $-846.0M | $-0.74 | — |
| Q1 2024 | $3.82B | 46.4% | $-218.0M | $-139.0M | $-0.13 | — |
| Q4 2023 | $4.46B | 54.2% | $756.0M | $463.0M | $0.41 | — |
| FY 2023 | $15.85B | 48.2% | $433.0M | $-559.0M | $-0.50 | — |